Enhanced synergy between fluticasone propionate and salmeterol inhaled from a single inhaler versus separate inhalers

被引:183
作者
Nelson, HS
Chapman, KR
Pyke, SD
Johnson, M
Pritchard, JN
机构
[1] Natl Jewish Med & Res Ctr, Denver, CO 80206 USA
[2] Univ Hlth Network, Asthma & Airway Ctr, Toronto, ON, Canada
[3] GlaxoSmithKline, Greenford, Middx, England
关键词
fluticasone propionate; salmeterol; synergy; asthma; Advair/Seretide; combination therapy;
D O I
10.1067/mai.2003.1558
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Background: The coadministration of long-acting inhaled beta(2)-agonists and inhaled corticosteroids is the most effective treatment for persistent asthma. Objective: This meta-analysis aimed to determine the efficacy of fluticasone propionate and salmeterol inhaled from a single inhaler (combination therapy) or from separate inhalers (concurrent therapy). Methods: Four similarly designed double-blind studies individually confirmed equivalence between combination and concurrent therapy on the basis of the primary efficacy measure (morning peak expiratory flow [PEF]). Each study showed a consistent trend in favor of combination therapy. Individual patient data from these studies were combined to provide overall estimates of treatment effect for morning PEF and other efficacy measures. Results: Fixed-effects meta-analysis showed a significant advantage for combination therapy compared with concurrent therapy in morning PEF (mean difference between groups in change from baseline over 12 weeks of 5.4 L/min; P = .006; 95% CI = 1.5-9.2). Logistic regression analysis showed that the odds of achieving a greater than 15 or greater than 30 L/min improvement with combination therapy were increased by approximately 40% compared with those after concurrent therapy (15 L/min: odds ratio = 1.42, P = .008, 95% CI = 1.1-1.8; 30 L/min: odds ratio = 1.40, P = .006, 95% CI = 1.1-1.8), representing an additional 7% to 9% and 5% to 14% more patients, respectively, on combination therapy responding compared with those on concurrent therapy. Conclusion: The meta-analysis indicates that the fluticasone propionate plus salmeterol combination offers the potential for increased clinical efficacy over concurrent use of the same doses of the same 2 drugs. After administration from a single inhaler, fluticasone propionate and salmeterol might codeposit in the airways. It is hypothesized that this codeposition offers an increased opportunity for synergistic interaction to occur.
引用
收藏
页码:29 / 36
页数:8
相关论文
共 41 条
[1]  
Anenden V., 1998, European Respiratory Journal, V12, p157S
[2]  
ASHURST IC, 1998, EUR RESPIR J, V15, pS93
[3]   Salmeterol/fluticasone propionate (50/500 μg) in combination in a Diskus® inhaler (Seretide®) is effective and safe in the treatment of steroid-dependent asthma [J].
Aubier, M ;
Pieters, WR ;
Schlösser, NJJ ;
Steinmetz, KO .
RESPIRATORY MEDICINE, 1999, 93 (12) :876-884
[4]   Glucocorticoids induce beta(2)-adrenergic receptor function in human nasal mucosa [J].
Baraniuk, JN ;
Ali, M ;
Brody, D ;
Maniscalco, J ;
Gaumond, E ;
Fitzgerald, T ;
Wong, G ;
Yuta, A ;
Mak, JCW ;
Barnes, PJ ;
Bascom, R ;
Troost, T .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1997, 155 (02) :704-710
[5]   Scientific rationale for inhaled combination therapy with long-acting β2-agonists and corticosteroids [J].
Barnes, PJ .
EUROPEAN RESPIRATORY JOURNAL, 2002, 19 (01) :182-191
[6]   Salmeterol/fluticasone combination inhaler - A new, effective and well tolerated treatment for asthma [J].
Bateman, ED ;
Britton, M ;
Carrillo, J ;
Almeida, J ;
Wixon, C .
CLINICAL DRUG INVESTIGATION, 1998, 16 (03) :193-201
[7]   Comparison of fluticasone propionate-salmeterol combination therapy and montelukast in patients who are symptomatic on short-acting β2-agonists alone [J].
Calhoun, WJ ;
Nelson, HS ;
Nathan, RA ;
Pepsin, PJ ;
Kalberg, C ;
Emmett, A ;
Rickard, KA ;
Dorinsky, P .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2001, 164 (05) :759-763
[8]  
Chapman K R, 1999, Can Respir J, V6, P45
[9]   A DOSE-RANGING STUDY OF FLUTICASONE PROPIONATE IN ADULT PATIENTS WITH MODERATE ASTHMA [J].
DAHL, R ;
LUNDBACK, B ;
MALO, JL ;
MAZZA, JA ;
NIEMINEN, MM ;
SAARELAINEN, P ;
BARNACLE, H .
CHEST, 1993, 104 (05) :1352-1358
[10]   METAANALYSIS IN CLINICAL-TRIALS [J].
DERSIMONIAN, R ;
LAIRD, N .
CONTROLLED CLINICAL TRIALS, 1986, 7 (03) :177-188